David Neustaedter, Ph.D.

Venture Partner at Deerfield Management · Joined 2022

Biography

David Neustaedter, Ph.D., is a Venture Partner on Deerfield's Medical Technologies team and joined the firm in 2022. Before Deerfield he spent seven years as a Vice President at Medtronic Ventures and, before Medtronic's merger with Covidien, a further seven years with Covidien including five years as a Vice President of Venture Capital. He has also held positions at Stryker Development, Leerink Swann/MEDACorp Strategy Consulting, Fletcher Spaght and Braun Consulting. He holds a B.Sc. in Cellular, Molecular, and Microbial Biology from the University of Calgary, an M.B.A. from Yale University and a Ph.D. in Molecular Biology from the University of British Columbia. SEC Form D filings name him as a director of Lunair Medical, Inc., Reprieve Cardiovascular, Inc., R3 Vascular Inc. and SpectraWAVE, Inc., all of which appear on Deerfield's portfolio page.

Education

• University of Calgary, B.Sc. in Cellular, Molecular, and Microbial Biology
• Yale University, M.B.A.
• University of British Columbia, Ph.D. in Molecular Biology

Previous Experience

• Braun Consulting
• Fletcher Spaght
• Leerink Swann/MEDACorp Strategy Consulting
• Stryker Development
• Covidien - seven years, including five years as Vice President of Venture Capital
• Medtronic Ventures - Vice President, seven years

Notable Investments

Board Seats

• Director, Lunair Medical, Inc. - Named as a Director in the issuer's Form D filed 15 September 2025. Lunair Medical is listed on Deerfield's own portfolio page.
• Director, Reprieve Cardiovascular, Inc. - Named as a Director in the issuer's Form D filed 5 June 2025. Reprieve Cardiovascular is listed on Deerfield's own portfolio page.

Career Timeline

Sources & References